Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (1-10 of 435) with videos related to

Pageof 44
Sort By:
Nature Reviews. Rheumatology|May 16, 2025
How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritisVibeke Strand
Arthritis and Rheumatism|April 13, 2004
Counterpoint from the trenches: a pragmatic approach to therapeutic trials in rheumatoid arthritisVibeke Strand
Rheumatology and Therapy|August 9, 2024
Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RAVibeke Strand
Autoimmunity Reviews|February 24, 2007
Lessons learned from clinical trials in SLEVibeke Strand
American Journal of Orthopedics (Belle Mead, N.J.)|May 12, 2007
Selective T-cell costimulation modulation: a new approach to treating rheumatoid arthritisVibeke Strand
The Lancet. Rheumatology|January 27, 2024
Long-term safety and efficacy of tofacitinib up to 48 months in psoriatic arthritisVibeke Strand
Journal of Cardiovascular Pharmacology|June 21, 2006
Expectations from patients with rheumatoid arthritis regarding COX-2s: cutting to the heart of the matterVibeke Strand
Lancet (London, England)|December 25, 2007
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?Vibeke Strand
Nature Reviews. Rheumatology|June 7, 2020
Minimizing efficacy differences between phase II and III RCTsVibeke Strand
RMD Open|February 18, 2021
RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?Vibeke Strand
Pageof 44

Showing results (1-10 of 435) with videos related to

Sort By:
Pageof 44
Nature Reviews. Rheumatology|May 16, 2025
How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritisVibeke Strand
Arthritis and Rheumatism|April 13, 2004
Counterpoint from the trenches: a pragmatic approach to therapeutic trials in rheumatoid arthritisVibeke Strand
Rheumatology and Therapy|August 9, 2024
Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RAVibeke Strand
Autoimmunity Reviews|February 24, 2007
Lessons learned from clinical trials in SLEVibeke Strand
American Journal of Orthopedics (Belle Mead, N.J.)|May 12, 2007
Selective T-cell costimulation modulation: a new approach to treating rheumatoid arthritisVibeke Strand
The Lancet. Rheumatology|January 27, 2024
Long-term safety and efficacy of tofacitinib up to 48 months in psoriatic arthritisVibeke Strand
Journal of Cardiovascular Pharmacology|June 21, 2006
Expectations from patients with rheumatoid arthritis regarding COX-2s: cutting to the heart of the matterVibeke Strand
Lancet (London, England)|December 25, 2007
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?Vibeke Strand
Nature Reviews. Rheumatology|June 7, 2020
Minimizing efficacy differences between phase II and III RCTsVibeke Strand
RMD Open|February 18, 2021
RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?Vibeke Strand
Pageof 44